This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seedat, J.
Right arrow Articles by Sahly, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seedat, J.
Right arrow Articles by Sahly, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2006, p. 4217-4219, Vol. 50, No. 12
0066-4804/06/$08.00+0     doi:10.1128/AAC.00518-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Rapid Emergence of Resistance to Linezolid during Linezolid Therapy of an Enterococcus faecium Infection{triangledown}

Jamela Seedat,1 Günther Zick,2 Ingo Klare,3 Carola Konstabel,3 Norbert Weiler,2 and Hany Sahly1*

Institute for Infection Medicine, Brunswiker Str. 4,1 Department of Anaesthesiology and Intensive Care Medicine, Schwanenweg 21, University Hospital Schleswig-Holstein, Campus Kiel, D-24105 Kiel,2 Robert Koch Institute, Wernigerode Branch, Burgstr. 37, D-38855 Wernigerode, Germany3

Received 27 April 2006/ Returned for modification 8 May 2006/ Accepted 6 September 2006

We report the emergence of linezolid resistance (MICs of 16 to 32 mg/liter) in clonally related vancomycin-susceptible and -resistant Enterococcus faecium isolates from an intensive care unit patient after 12 days of linezolid therapy. Only linezolid-susceptible isolates of the same clone were detected at 28 days after termination of linezolid therapy.

* Corresponding author. Mailing address: Institute for Infection Medicine, Faculty of Medicine, University Hospital Schleswig-Holstein, Campus Kiel, Brunswiker Str. 4, D-24105 Kiel, Germany. Phone: 49 431 597 3316. Fax: 49 431 597 3296. E-mail: sahly{at}infmed.uni-kiel.de.

{triangledown} Published ahead of print on 18 September 2006.

Antimicrobial Agents and Chemotherapy, December 2006, p. 4217-4219, Vol. 50, No. 12
0066-4804/06/$08.00+0     doi:10.1128/AAC.00518-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Skripkin, E., McConnell, T. S., DeVito, J., Lawrence, L., Ippolito, J. A., Duffy, E. M., Sutcliffe, J., Franceschi, F. (2008). R{chi}-01, a New Family of Oxazolidinones That Overcome Ribosome-Based Linezolid Resistance. Antimicrob. Agents Chemother. 52: 3550-3557 [Abstract] [Full Text]  
  • Lawrence, L., Danese, P., DeVito, J., Franceschi, F., Sutcliffe, J. (2008). In Vitro Activities of the Rx-01 Oxazolidinones against Hospital and Community Pathogens. Antimicrob. Agents Chemother. 52: 1653-1662 [Abstract] [Full Text]  
  • Werner, G., Bartel, M., Wellinghausen, N., Essig, A., Klare, I., Witte, W., Poppert, S. (2007). Detection of Mutations Conferring Resistance to Linezolid in Enterococcus spp. by Fluorescence In Situ Hybridization. J. Clin. Microbiol. 45: 3421-3423 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»